A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas

Emily Chan, Daniel Mulkerin, Mace Rothenberg, Kyle D. Holen, Albert Lockhart, James Thomas, Jordan Berlin

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Introduction: Current standard therapy for advanced pancreas cancer includes the use of gemcitabine or a gemcitabine-based chemotherapy regimen. Based on pre-clinical data, the combination of CEP-701, an inhibitor of tyrosine kinases including Flt-3, TRK-A/B and JCK-2, with gemcitabine appeared promising. Methods: Two clinical sites were chosen for this phase I trial, one scheduled to start gemcitabine prior to CEP-701 and one scheduled to start CEP-701 prior to gemcitabine. Gemcitabine was given at a dose of 1,000 mg/m 2 over 30 min each week for 3 weeks in a row followed by 1 week off. CEP 701 was taken orally twice daily at doses ranging from 20 mg bid to 40 mg bid. Pharmacokinetics of both drugs were determined to assess for any drug-drug interactions. Results: Eighteen patients were enrolled and 17 received at least one dose of study drug. Nine patients experienced serious adverse events, but only one patient's toxicity was attributed as possibly secondary to study drug. No radiologic responses were seen. No significant pharmacokinetic interactions were observed between gemcitabine and CEP 701. The combination was well-tolerated, and the MTD was not reached in this study. Conclusions: No unexpected toxicities were seen for this combination. Although too few patients were enrolled to fully evaluate efficacy, there was not significant evidence for pursuing this combination further in pancreas cancer. The maximum tolerated dose of the combination was not determined secondary to the early termination of the study.

Original languageEnglish (US)
Pages (from-to)241-247
Number of pages7
JournalInvestigational New Drugs
Volume26
Issue number3
DOIs
StatePublished - Jun 1 2008
Externally publishedYes

Fingerprint

gemcitabine
Pancreas
Adenocarcinoma
Pancreatic Neoplasms
Pharmaceutical Preparations
Pharmacokinetics
Maximum Tolerated Dose
lestaurtinib
Drug Interactions
Protein-Tyrosine Kinases

Keywords

  • CEP-701
  • Pancreatic cancer
  • Phase I trial

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas. / Chan, Emily; Mulkerin, Daniel; Rothenberg, Mace; Holen, Kyle D.; Lockhart, Albert; Thomas, James; Berlin, Jordan.

In: Investigational New Drugs, Vol. 26, No. 3, 01.06.2008, p. 241-247.

Research output: Contribution to journalArticle

Chan, Emily ; Mulkerin, Daniel ; Rothenberg, Mace ; Holen, Kyle D. ; Lockhart, Albert ; Thomas, James ; Berlin, Jordan. / A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas. In: Investigational New Drugs. 2008 ; Vol. 26, No. 3. pp. 241-247.
@article{704ab2b8f7d64042b22a418f86041823,
title = "A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas",
abstract = "Introduction: Current standard therapy for advanced pancreas cancer includes the use of gemcitabine or a gemcitabine-based chemotherapy regimen. Based on pre-clinical data, the combination of CEP-701, an inhibitor of tyrosine kinases including Flt-3, TRK-A/B and JCK-2, with gemcitabine appeared promising. Methods: Two clinical sites were chosen for this phase I trial, one scheduled to start gemcitabine prior to CEP-701 and one scheduled to start CEP-701 prior to gemcitabine. Gemcitabine was given at a dose of 1,000 mg/m 2 over 30 min each week for 3 weeks in a row followed by 1 week off. CEP 701 was taken orally twice daily at doses ranging from 20 mg bid to 40 mg bid. Pharmacokinetics of both drugs were determined to assess for any drug-drug interactions. Results: Eighteen patients were enrolled and 17 received at least one dose of study drug. Nine patients experienced serious adverse events, but only one patient's toxicity was attributed as possibly secondary to study drug. No radiologic responses were seen. No significant pharmacokinetic interactions were observed between gemcitabine and CEP 701. The combination was well-tolerated, and the MTD was not reached in this study. Conclusions: No unexpected toxicities were seen for this combination. Although too few patients were enrolled to fully evaluate efficacy, there was not significant evidence for pursuing this combination further in pancreas cancer. The maximum tolerated dose of the combination was not determined secondary to the early termination of the study.",
keywords = "CEP-701, Pancreatic cancer, Phase I trial",
author = "Emily Chan and Daniel Mulkerin and Mace Rothenberg and Holen, {Kyle D.} and Albert Lockhart and James Thomas and Jordan Berlin",
year = "2008",
month = "6",
day = "1",
doi = "10.1007/s10637-008-9118-3",
language = "English (US)",
volume = "26",
pages = "241--247",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas

AU - Chan, Emily

AU - Mulkerin, Daniel

AU - Rothenberg, Mace

AU - Holen, Kyle D.

AU - Lockhart, Albert

AU - Thomas, James

AU - Berlin, Jordan

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Introduction: Current standard therapy for advanced pancreas cancer includes the use of gemcitabine or a gemcitabine-based chemotherapy regimen. Based on pre-clinical data, the combination of CEP-701, an inhibitor of tyrosine kinases including Flt-3, TRK-A/B and JCK-2, with gemcitabine appeared promising. Methods: Two clinical sites were chosen for this phase I trial, one scheduled to start gemcitabine prior to CEP-701 and one scheduled to start CEP-701 prior to gemcitabine. Gemcitabine was given at a dose of 1,000 mg/m 2 over 30 min each week for 3 weeks in a row followed by 1 week off. CEP 701 was taken orally twice daily at doses ranging from 20 mg bid to 40 mg bid. Pharmacokinetics of both drugs were determined to assess for any drug-drug interactions. Results: Eighteen patients were enrolled and 17 received at least one dose of study drug. Nine patients experienced serious adverse events, but only one patient's toxicity was attributed as possibly secondary to study drug. No radiologic responses were seen. No significant pharmacokinetic interactions were observed between gemcitabine and CEP 701. The combination was well-tolerated, and the MTD was not reached in this study. Conclusions: No unexpected toxicities were seen for this combination. Although too few patients were enrolled to fully evaluate efficacy, there was not significant evidence for pursuing this combination further in pancreas cancer. The maximum tolerated dose of the combination was not determined secondary to the early termination of the study.

AB - Introduction: Current standard therapy for advanced pancreas cancer includes the use of gemcitabine or a gemcitabine-based chemotherapy regimen. Based on pre-clinical data, the combination of CEP-701, an inhibitor of tyrosine kinases including Flt-3, TRK-A/B and JCK-2, with gemcitabine appeared promising. Methods: Two clinical sites were chosen for this phase I trial, one scheduled to start gemcitabine prior to CEP-701 and one scheduled to start CEP-701 prior to gemcitabine. Gemcitabine was given at a dose of 1,000 mg/m 2 over 30 min each week for 3 weeks in a row followed by 1 week off. CEP 701 was taken orally twice daily at doses ranging from 20 mg bid to 40 mg bid. Pharmacokinetics of both drugs were determined to assess for any drug-drug interactions. Results: Eighteen patients were enrolled and 17 received at least one dose of study drug. Nine patients experienced serious adverse events, but only one patient's toxicity was attributed as possibly secondary to study drug. No radiologic responses were seen. No significant pharmacokinetic interactions were observed between gemcitabine and CEP 701. The combination was well-tolerated, and the MTD was not reached in this study. Conclusions: No unexpected toxicities were seen for this combination. Although too few patients were enrolled to fully evaluate efficacy, there was not significant evidence for pursuing this combination further in pancreas cancer. The maximum tolerated dose of the combination was not determined secondary to the early termination of the study.

KW - CEP-701

KW - Pancreatic cancer

KW - Phase I trial

UR - http://www.scopus.com/inward/record.url?scp=42549172020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42549172020&partnerID=8YFLogxK

U2 - 10.1007/s10637-008-9118-3

DO - 10.1007/s10637-008-9118-3

M3 - Article

VL - 26

SP - 241

EP - 247

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -